Cosmetic treatment with OnabotulinumtoxinA (Botox®): relationship between initial clinical assessment, dosage and costs

Authors

  • Raphael Chu Allergan Produtos Farmacêuticos Ltda.
  • Fábio Saito Allergan Produtos Farmacêuticos Ltda.
  • Thiago Biasi Allergan Internacional

DOI:

https://doi.org/10.21115/JBES.v8.n2.p164-171

Keywords:

botulinum, toxin, cost, dosage, onabotulinumtoxinA

Abstract

Objective: The aim of this study is to demonstrate how the correct clinical assessment can influence the dosage used in the cosmetic treatment with onabotulinumtoxinA (Botox®, Allergan, Inc., Dublin, UK) and its consequent relationship to cost and value of long-term treatment. Method: Four patients were selected for cosmetic treatment with Botulinum Toxin Type A. Patients` pictures were taken pre procedure, 15 days post procedure, 3, 4, 7 and 10 months post procedure. The patient initial evaluation, technique, objective and dosages used were commented by the doctor who performed the treatment. Evaluation and comments of the pictures post procedure were performed by another medical specialist. Results: All patients had the frontal, glabellar, and periorbital areas treated. Total doses used for each patient were as follows: patient 1: 64U; patient 2: 69U; patient 3: 78U and patient 4: 81U. Conclusions: The correct clinical assessment is essential for proper planning of cosmetic treatment with Botox®. Long lasting results, with high satisfaction rates among patients, are associated with the correct choice of doses. The cost of Botox® cosmetic treatment should be evaluated comprehensively and in a long term manner.

Downloads

Download data is not yet available.

Published

2016-08-20

How to Cite

Chu, R., Saito, F., & Biasi, T. (2016). Cosmetic treatment with OnabotulinumtoxinA (Botox®): relationship between initial clinical assessment, dosage and costs. Jornal Brasileiro De Economia Da Saúde, 8(2), 164–171. https://doi.org/10.21115/JBES.v8.n2.p164-171

Issue

Section

Artigos